This paper describes an optimization strategy of the highly active vinyl ketone 3 which was recognized as a strong inhibitor of rhodesain of Trypanosoma brucei rhodesiense, endowed with a k(second) value of 67 X 10(6) M-1 min(-1) coupled with a high binding affinity (K-i = 38 pM). We now report a new structure-activity relationship study based on structural variations on the P3, P2, and P1' sites which led us to identify two potent lead compounds, i.e., vinyl ketones 4h and 4k. Vinyl ketone 4h showed an impressive potency toward rhodesain (k(second) = 8811 X 10(5)) coupled to a good antiparasitic activity (EC50 = 3.6 mu M), while vinyl ketone 4k proved to possess the highest binding affinity toward the trypanosomal protease (K-i = 0.6 pM) and a submicromolar antiparasitic activity (EC50 = 0.67 mu M), thus representing new lead compounds in the drug discovery process for the treatment of Human African Trypanosomiasis.

Optimization Strategy of Novel Peptide-Based Michael Acceptors for the Treatment of Human African Trypanosomiasis

Roberta Ettari
Primo
;
Santo Previti
Secondo
;
Santina Maiorana;Maria Zappalà
Ultimo
2019-01-01

Abstract

This paper describes an optimization strategy of the highly active vinyl ketone 3 which was recognized as a strong inhibitor of rhodesain of Trypanosoma brucei rhodesiense, endowed with a k(second) value of 67 X 10(6) M-1 min(-1) coupled with a high binding affinity (K-i = 38 pM). We now report a new structure-activity relationship study based on structural variations on the P3, P2, and P1' sites which led us to identify two potent lead compounds, i.e., vinyl ketones 4h and 4k. Vinyl ketone 4h showed an impressive potency toward rhodesain (k(second) = 8811 X 10(5)) coupled to a good antiparasitic activity (EC50 = 3.6 mu M), while vinyl ketone 4k proved to possess the highest binding affinity toward the trypanosomal protease (K-i = 0.6 pM) and a submicromolar antiparasitic activity (EC50 = 0.67 mu M), thus representing new lead compounds in the drug discovery process for the treatment of Human African Trypanosomiasis.
2019
File in questo prodotto:
File Dimensione Formato  
Ettari_J Med Chem_2019.pdf

solo gestori archivio

Tipologia: Versione Editoriale (PDF)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 1.75 MB
Formato Adobe PDF
1.75 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11570/3148075
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 25
  • ???jsp.display-item.citation.isi??? 25
social impact